Teva Pharmaceutical announced the launch of a generic version of Uceris

Posted on Jul 14, 2018 by Ifi Reporter

 Teva Pharmaceutical Industries announced the launch of a generic version of Uceris extended-release tablets, 9 mg, in the U.S.

Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Uceris had annual sales of approximately $196 million in the U.S., according to IMS data as of May 2018.

The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial. “We continue to be focused on bringing affordable generic treatment options to our customers, including those living with chronic, life-long conditions like ulcerative colitis.”

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. 

 

 

 

 


ABOUT IFI TODAY

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum

Newsline

Veteran Israeli information security company Siren is laying off all 121 of its employees

Feb 2, 2023 by Ifi Reporter

The veteran Israeli information security company Siren (formerly Comtouch) is laying off all 121 of its employees. The company, which was caught in a liquidity crisis, announced today (Wednesday) that it is considering closing its operations. In Israel the company employs about 50 people. In... Continue reading →

Histadrut officially resumed negotiations on a new wage agreement with the government

Jan 29, 2023 by Ifi Reporter

Seven months after the discussions on a new wage agreement in the economy for the public sector were halted due to the fall of the government and the dissolution of the Knesset, the heads of the Ministry of Finance and the Histadrut officially resumed negotiations. An increase of 2.5% every... Continue reading →

The venture capital funds Disruptive and Disruptive intend to withdraw their funds from Israel

Jan 27, 2023 by Ifi Reporter

The venture capital funds Disruptive and Disruptive AI of Tal Baranach have informed their investors of their intention to withdraw the fund's funds from Israel and transfer them abroad. The funds together manage 250 million dollars. In doing so, they join the announcement made this morning... Continue reading →


Testimonials

No testimonials. Click here to add your testimonials.